摘要
目的:探讨单唾液酸四己糖神经节苷脂钠联合多奈哌齐对合并轻度认知功能障碍帕金森(PD-MCI)患者认知功能及日常生活能力量表(ADL)评分的影响。方法:选取我院2018年1月—2019年9月收治的PD-MCI患者92例,随机数字表法分组,各46例。对照组给予多奈哌齐治疗,观察组给予单唾液酸四己糖神经节苷脂钠联合多奈哌齐治疗。两组均持续治疗3个月。对比两组治疗前后蒙特利尔认知评估量表(MOCA)、简易智力精神状态检查量表(MMSE)、ADL、帕金森病生活质量量表(PDQ-39)评分及血清脑源性神经营养因子(BDNF)、β-淀粉样蛋白1-42(Aβ1-42)水平及不良反应发生率。结果:治疗后观察组MOCA、MMSE评分高于对照组(P<0.05);治疗后观察组ADL、PDQ-39评分低于对照组(P<0.05);治疗后观察组血清BDNF、Aβ1-42水平高于对照组(P<0.05);两组不良反应发生率无显著差异(P>0.05)。结论:单唾液酸四己糖神经节苷脂钠联合多奈哌齐治疗PD-MCI患者,可调节血清BDNF、Aβ1-42水平,改善认知功能,提高ADL评分与生活质量,且安全性高。
Objective:To investigate the effect of monosialotetrahexose ganglioside sodium combined with donepezil on the cognitive function and daily living ability scale(ADL)scores of patients with mild cognitive impairment Parkinson's disease(PD-MCI).Methods:A total of 92 patients with PD-MCI who were admitted to our hospital from January 2018 to September 2019 were selected and grouped according to the random number table method,each with 46 patients.The control group was treated with donepezil,and the observation group was given monosialotetrahexose ganglioside sodium combined with donepezil.Both groups continued treatment for 3 months.The Montreal Cognitive Assessment Scale(MOCA),Mini-Mental State Examination Scale(MMSE),ADL,Parkinson's Disease Quality of Life Scale(PDQ-39)scores,serum brain-derived neurotrophic factor(BDNF),β-amyloid 1-42(Aβ1-42)levels before and after treatment and incidence of adverse reactions were compared between the two groups.Results:After treatment,the MOCA and MMSE scores of the observation group were higher than those of the control group(P<0.05);after treatment,the ADL and PDQ-39 scores of the observation group were lower than those of the control group(P<0.05);the levels of serum BDNF and Aβ1-42 in the observation group after treatment were higher than those in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Monosialotetrahexose ganglioside sodium combined with donepezil in patients with PD-MCI can adjust serum BDNF and Aβ1-42 levels and improve cognitive function,improve ADL score and quality of life,and have high safety.
作者
郭国志
GUO Guo-zhi(Department of Neurology,Huixian People's Hospital Huixian,Huixian Henan 453600,China)
出处
《药品评价》
CAS
2020年第8期30-31,45,共3页
Drug Evaluation
作者简介
郭国志,主治医师,研究方向为神经内科学。E-mail:yunfu56456@163.com。
